From killers to strategists: CAR T cells enter their multifunctional era
Summary
A review of 1,801 registered CAR T clinical trials shows that multifunctional designs now account for 533 trials and 33% of new CAR T products submitted for clinical testing in 2025. The field is shifting toward multitargeted, safety-controlled, cytokine-secreting, and checkpoint-modulating CAR T cells, but manufacturing, regulation, and limited clinical outcome data remain key barriers.
Description
A review of 1,801 registered CAR T clinical trials shows that multifunctional designs now account for 533 trials and 33% of new CAR T products submitted for clinical testing in 2025. The field is shifting toward multitargeted, safety-controlled, cytokine-secreting, and checkpoint-modulating CAR T cells, but manufacturing, regulation, and limited clinical outcome data remain key barriers.
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source